TAAR1 and schizophrenia: Indeed, TAAR1/DA D2 receptor interactions, and their downstream signalling pathways converging on GSK-3, may provide alternative targets for the development of new treatments not only for stimulant addiction but also for other disorders involving DA dysfunction, including schizophrenia and bipolar disorder.